Related Experiment Video
Updated: Jul 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Design of second generation HIV-1 integrase inhibitors
Jinxia Deng1, Raveendra Dayam, Laith Q Al-Mawsawi
1Department of Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, California 90089, USA.
Abstract:
The prospect of HIV-1 integrase (IN) as a therapeutically viable retroviral drug target is on the verge of realization. The observed preclinical and clinical performance of beta-diketo containing and naphthyridine carboxamide compounds provides direct proof for the clinical application of IN inhibition. These validated lead compounds are useful in the design and development of second generation IN inhibitors. The results from preclinical and clinical studies on the first generation IN inhibitors reiterate a demand for novel second generation inhibitors with improved pharmacokinetic and metabolic properties. Pharmacophore-based drug design techniques facilitate the discovery of novel compounds on the basis of validated lead compounds specific for a drug target. In this article we have comprehensively reviewed the application of pharmacophore-based drug design methods in the field of IN inhibitor discovery.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Inhibitors Of Virion Release

